Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

SemBioSys Genetics of Canada Forms JV with Tasly Pharma

publication date: Oct 11, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
SemBioSys Genetics of Canada has formed a China JV with Tasly Pharma of Tianjin. In exchange for a 30% stake in the JV, SemBioGenetics will contribute its plant-made insulin and insulin analogues (excluding territories in which SemBioSys is pursuing other deals). The insulin products are in clinical development. SemBioSys positions the insulin, which is produced using safflower seeds, as a low-cost insulin biosimilar. More details....

Stock Symbols: (TSX: SBS) (SHA: 600535)

Share this with colleagues:  

This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors